APOBEC3G/3A expression in human immunodeficiency virus type 1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz

Daniela A. Covino, Cristina Purificato, Laura Catapano, Clementina M. Galluzzo, Maria Cristina Gauzzi, Stefano Vella, Eric Lefebvre, Star Seyedkazemi, Mauro Andreotti, Laura Fantuzzi

Research output: Contribution to journalArticle

Abstract

Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.

Original languageEnglish
Article number1839
JournalFrontiers in Immunology
Volume9
Issue numberAUG
DOIs
Publication statusPublished - Aug 8 2018

Fingerprint

efavirenz
HIV-1
Virus Diseases
Retroviridae Infections
Cytidine Deaminase
CD4-CD8 Ratio
Therapeutics
CD4 Lymphocyte Count
Virus Replication
Disease Progression
Blood Cells
Inflammation
TAK-652
Enzymes

Keywords

  • Antiretroviral therapy
  • APOBEC3A
  • APOBEC3G
  • Chronic inflammation
  • Disease progression
  • Cenicriviroc

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{cea1cda70c6b44239b3c1725a557f4bb,
title = "APOBEC3G/3A expression in human immunodeficiency virus type 1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz",
abstract = "Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.",
keywords = "Antiretroviral therapy, APOBEC3A, APOBEC3G, Chronic inflammation, Disease progression, Cenicriviroc",
author = "Covino, {Daniela A.} and Cristina Purificato and Laura Catapano and Galluzzo, {Clementina M.} and Gauzzi, {Maria Cristina} and Stefano Vella and Eric Lefebvre and Star Seyedkazemi and Mauro Andreotti and Laura Fantuzzi",
year = "2018",
month = "8",
day = "8",
doi = "10.3389/fimmu.2018.01839",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "AUG",

}

TY - JOUR

T1 - APOBEC3G/3A expression in human immunodeficiency virus type 1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz

AU - Covino, Daniela A.

AU - Purificato, Cristina

AU - Catapano, Laura

AU - Galluzzo, Clementina M.

AU - Gauzzi, Maria Cristina

AU - Vella, Stefano

AU - Lefebvre, Eric

AU - Seyedkazemi, Star

AU - Andreotti, Mauro

AU - Fantuzzi, Laura

PY - 2018/8/8

Y1 - 2018/8/8

N2 - Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.

AB - Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.

KW - Antiretroviral therapy

KW - APOBEC3A

KW - APOBEC3G

KW - Chronic inflammation

KW - Disease progression

KW - Cenicriviroc

UR - http://www.scopus.com/inward/record.url?scp=85054929369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054929369&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.01839

DO - 10.3389/fimmu.2018.01839

M3 - Article

AN - SCOPUS:85054929369

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - AUG

M1 - 1839

ER -